Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (r-)-3-isobutyl Gaba
2. (s)-3-(aminomethyl)-5-methylhexanoic Acid
3. (s+)-3-isobutyl Gaba
4. 1008, Ci
5. 3 Isobutyl Gaba
6. 3-(aminomethyl)-5-methylhexanoic Acid
7. 3-isobutyl Gaba
8. Ci 1008
9. Ci-1008
10. Ci1008
11. Gaba, 3-isobutyl
12. Lyrica
1. 148553-50-8
2. Lyrica
3. (s)-3-(aminomethyl)-5-methylhexanoic Acid
4. 3-isobutyl Gaba
5. (3s)-3-(aminomethyl)-5-methylhexanoic Acid
6. Ci-1008
7. (s)-pregabalin
8. Hexanoic Acid, 3-(aminomethyl)-5-methyl-, (3s)-
9. Vronogabic
10. Ci 1008
11. Pregabalin Mylan
12. Pregabalin Sandoz
13. Pd 144723
14. Pd-144723
15. Pregabalin Zentiva
16. Pregabalin Sandoz Gmbh
17. (s)-3-isobutyl Gaba
18. Chembl1059
19. Chebi:64356
20. (3s)-3-(aminomethyl)-5-methyl-hexanoic Acid
21. 55jg375s6m
22. Ynp-1807
23. Nsc-759256
24. Hexanoic Acid, 3-(aminomethyl)-5-ethyl-, (3s)-
25. (r-)-3-isobutyl Gaba
26. Pregabalin [usan]
27. Hexanoic Acid, 3-(aminomethyl)-5-methyl-, (s)-
28. Pregabalina
29. Pregabaline
30. Nervalin
31. Pregablin
32. Unii-55jg375s6m
33. Hsdb 7530
34. Pregabalin [usan:inn:ban:jan]
35. Ncgc00095186-01
36. Pregabalin- Bio-x
37. Lyrica (tn)
38. Mfcd00917044
39. Lyrica Cr
40. Pregabalin [mi]
41. (s)-3-(aminomethyl)-5-methylhexanoicacid
42. Pregabalin [inn]
43. Pregabalin [jan]
44. Pregabalin [hsdb]
45. Pregabalin [vandf]
46. Pregabalin [mart.]
47. Schembl8227
48. Dsstox_cid_25950
49. Dsstox_rid_81246
50. Pregabalin [usp-rs]
51. Pregabalin [who-dd]
52. Dsstox_gsid_45950
53. Pregabalin (jan/usan/inn)
54. Pregabalin [ema Epar]
55. Pregabalin Mylan Pharma
56. (s)-(+)-4-amino-3-(2-methylpropyl)butanoic Acid
57. Gtpl5484
58. Zinc5152
59. Dea No. 2782
60. Pregabalin, >=97% (nmr)
61. Dtxsid1045950
62. Pregabalin [orange Book]
63. Pregabalin [ep Monograph]
64. Hms3715j16
65. Pregabalin [usp Monograph]
66. Pregabalin 1.0 Mg/ml In Methanol
67. Tox21_111475
68. Bdbm50164279
69. Akos001476611
70. Akos005145504
71. Lyrica;ci-1008;pd-144723
72. Ac-1158
73. Ccg-221247
74. Cs-1247
75. Db00230
76. Ks-5378
77. Nsc 759256
78. (s)-3-aminomethyl-5-methylhexanoic Acid
79. Ncgc00346738-01
80. 121ge001
81. Bp163672
82. Hy-17414
83. (s)-3-aminomethyl-5-methyl-hexanoic Acid
84. Am20080369
85. Cas-148553-50-8
86. P2840
87. En300-92104
88. (3s)-3-(aminomethyl)-5-methyl Hexanoic Acid
89. (s)-(+)-3-aminomethyl-5-methylhexanoic Acid
90. D02716
91. Ab01563007_01
92. 553p508
93. A808784
94. Q412174
95. Sr-01000942257
96. Sr-01000942257-2
97. Pregabalin, Europepharmacopoeia (ep) Reference Standard
98. Z2757554242
99. 1414928-41-8
| Molecular Weight | 159.23 g/mol |
|---|---|
| Molecular Formula | C8H17NO2 |
| XLogP3 | -1.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 159.125928785 g/mol |
| Monoisotopic Mass | 159.125928785 g/mol |
| Topological Polar Surface Area | 63.3 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 123 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Lyrica |
| PubMed Health | Pregabalin (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:Pregabalin is a white to off-white, crystalline solid with... |
| Active Ingredient | Pregabalin |
| Dosage Form | Capsule; Solution |
| Route | oral; Oral |
| Strength | 20mg/ml; 200mg; 25mg; 150mg; 300mg; 75mg; 100mg; 50mg; 225mg |
| Market Status | Prescription |
| Company | Pf Prism; Cp Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Pregabalin |
| PubMed Health | Pregabalin (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:Pregabalin is a white to off-white, crystalline solid with... |
| Active Ingredient | Pregabalin |
| Dosage Form | Capsule; Solution |
| Route | oral; Oral |
| Strength | 20mg/ml; 200mg; 25mg; 150mg; 300mg; 75mg; 100mg; 50mg; 225mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Lupin; Sandoz; Watson Labs; Actavis Elizabeth; Teva Pharms; Wockhardt Usa |
| 3 of 4 | |
|---|---|
| Drug Name | Lyrica |
| PubMed Health | Pregabalin (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:Pregabalin is a white to off-white, crystalline solid with... |
| Active Ingredient | Pregabalin |
| Dosage Form | Capsule; Solution |
| Route | oral; Oral |
| Strength | 20mg/ml; 200mg; 25mg; 150mg; 300mg; 75mg; 100mg; 50mg; 225mg |
| Market Status | Prescription |
| Company | Pf Prism; Cp Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Pregabalin |
| PubMed Health | Pregabalin (By mouth) |
| Drug Classes | Anticonvulsant, Neuropathic Pain Agent |
| Drug Label | Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is:Pregabalin is a white to off-white, crystalline solid with... |
| Active Ingredient | Pregabalin |
| Dosage Form | Capsule; Solution |
| Route | oral; Oral |
| Strength | 20mg/ml; 200mg; 25mg; 150mg; 300mg; 75mg; 100mg; 50mg; 225mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Lupin; Sandoz; Watson Labs; Actavis Elizabeth; Teva Pharms; Wockhardt Usa |
Pregabalin is indicated for management of post-herpetic neuralgia. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 2412
Pregabalin is indicated for management of neuropathic pain associated with diabetic peripheral neuropathy. /Included in US product labe/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 2412
Pregabalin is indicated as an adjunctive therapy for adult patients with partial onset seizures. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 2412
The U.S. Food and Drug Administration ... has approved Lyrica (pregabalin), the first drug to treat fibromyalgia, a disorder characterized by pain, fatigue and sleep problems.
FDA; FDA News (P07-107). Available from, as of July 31, 2007: https://www.fda.gov/bbs/topics/NEWS/2007/NEW01656.html
Known hypersensitivity to pregabalin or any ingredient in the formulation.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2247
Because of the possibility of increased seizure frequency, anticonvulsant drugs, including pregabalin, should be withdrawn gradually and dosage reduced slowly over at least 1 week. Abrupt discontinuance of pregabalin has been associated with insomnia, nausea, headache, and diarrhea.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2247
In controlled studies, blurred vision, which was reported in 6 or 2% of patients receiving pregabalin or placebo, respectively, resolved in the majority of cases with continued dosing; less than 1% of patients required discontinuance of the drug. In addition, decreased visual acuity was reported in 7 or 5% of patients receiving pregabalin or placebo, respectively, while visual field changes were detected in 13 or 12% of patients receiving the drug or placebo, respectively, and funduscopic changes were observed in 2% of patients receiving pregabalin or placebo. The clinical importance of these ophthalmologic findings has not been elucidated. If visual disturbance persists, further ocular assessment should be considered, while more frequent assessment is recommended in patients who already are monitored for ocular conditions.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2247
Weight gain, which was related to dosage and duration of exposure to pregabalin, has been reported in patients receiving pregabalin. Weight gain did not appear to be associated with baseline body mass index (BMI), gender, or age and was not limited to patients with edema.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2247
For more Drug Warnings (Complete) data for PREGABALIN (20 total), please visit the HSDB record page.
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
FDA Label
* Neuropathic pain:
- Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.
* Epilepsy :
- Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised anxiety disorder:
- Lyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
* Epilepsy :
Pregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised Anxiety Disorder:
Pregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
* Neuropathic pain:
Pregabalin Mylan is indicated for the treatment of peripheral and central neuropathic pain in adults.
* Epilepsy :
Pregabalin Mylan is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised Anxiety Disorder:
Pregabalin Mylan is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Neuropathic pain
- Pregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.
Epilepsy
- Pregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised Anxiety Disorder
- Pregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
* Neuropathic pain:
- Pregabalin Zentiva k. s. is indicated for the treatment of peripheral and central neuropathic pain in adults.
* Epilepsy :
- Pregabalin Zentiva k. s. is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised anxiety disorder:
- Pregabalin Zentiva k. s. is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
Epilepsy
- Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
Generalised Anxiety Disorder
- Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
* Neuropathic pain:
- Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults.
* Epilepsy :
- Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised anxiety disorder:
- Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
* Epilepsy :
Pregabalin Sandoz GmbH is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised Anxiety Disorder:
Pregabalin Sandoz GmbH is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
* Neuropathic pain:
Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.
* Epilepsy :
Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
* Generalised Anxiety Disorder:
Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Alleviation of acute anxiety and fear associated with transportation and veterinary visits.
Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors. Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system. Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AX16
N03AX16
N03AX16
N03AX16
N03AX16
N03AX16
N03AX16
N03AX16
N03AX16
QN03AX16
N03AX16
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX16 - Pregabalin
Absorption
After oral dosing administered in the fasted state, pregabalin absorption is rapid, and extensive. Pregabalin oral bioavailability is reported to be 90% regardless of the dose. Cmax is attained within 1.5 hours after single or multiple doses, and steady state is attained within 24-48 hours with repeated administration. Both Cmax and AUC appear to be dose proportional. Food decreases the rate of pregabalin absorption and as a result, lowers the Cmax by an estimated 25-30% and increases the Tmax to approximately 3 hours. However, the effect of food does not appear to impact the total absorption of pregabalin in a way that is clinically relevant. As a result, pregabalin can be administered with or without food.
Route of Elimination
Pregabalin is almost exclusively eliminated in the urine. Further, based on preclinical studies, pregabalin does not appear to undergo racemization to the R enantiomer in the body.
Volume of Distribution
After oral administration of pregabalin, the reported apparent volume of distribution is roughly 0.5 L/kg. Although pregabalin is not very lipophilic, it is able to cross the blood brain barrier(BBB). System L transporters facilitate the transport of large amino acids across the BBB and it has been confirmed that pregabalin is a substrate. This information suggests that system L transporters are responsible for pregabalin uptake into the BBB. In rat models, pregabalin has been shown to cross the placenta.
Clearance
In young healthy subjects the mean renal clearance is estimated to be 67.0 to 80.9 mL mL/min. Given pregabalin's lack of plasma protein binding, this clearance rate suggests that renal tubular reabsorption is involved.
Pregabalin is well absorbed after oral administration ...
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2539
Following oral administration of pregabalin capsules under fasting conditions, peak plasma concentrations occur within 1.5 hours. Pregabalin oral bioavailability is >/=90% and is independent of dose. Following single- (25 to 300 mg) and multiple-dose (75 to 900 mg/day) administration, maximum plasma concentrations (C max ) and area under the plasma concentration-time curve (AUC) values increase linearly. Following repeated administration, steady state is achieved within 24 to 48 hours. Multiple-dose pharmacokinetics can be predicted from single-dose data.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2539
The rate of pregabalin absorption is decreased when given with food, resulting in a decrease in Cmax of approximately 25% to 30% and an increase in Tmax to approximately 3 hours. However, administration of pregabalin with food has no clinically relevant effect on the total absorption of pregabalin. Therefore, pregabalin can be taken with or without food.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2539
Pregabalin does not bind to plasma proteins. The apparent volume of distribution of pregabalin following oral administration is approximately 0.5 L/kg. Pregabalin is a substrate for system L transporter which is responsible for the transport of large amino acids across the blood brain barrier. Although there are no data in humans, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. In addition, pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2539
For more Absorption, Distribution and Excretion (Complete) data for PREGABALIN (8 total), please visit the HSDB record page.
Less than 2% of pregabalin is metabolized and it is excreted virtually unchanged in the urine.
Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabeled pregabalin, approximately 90% of the administered dose was recovered in the urine as unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, pregabalin (S-enantiomer) did not undergo racemization to the R-enantiomer in mice, rats, rabbits, or monkeys.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2540
The elimination half life of pregabalin is 6.3 hours.
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in subjects with normal renal function.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2540
Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models. By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide. In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action. Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.
Pregabalin is an anticonvulsant that is structurally related to the inhibitory CNS neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin also has demonstrated analgesic activity. Although pregabalin was developed as a structural analog of GABA, the drug does not bind directly to GABA-A, GABA-B, or benzodiazepine receptors; does not augment GABA-A responses in cultured neurons; and does not alter brain concentrations of GABA in rats or affect GABA uptake or degradation. However, in cultured neurons, prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2248
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues. ... In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, including glutamate, norepinephrine, and substance P, possibly by modulation of calcium channel function.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2248
Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 2539
Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. ... Potent binding to the alpha-2-delta site reduces depolarization-induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. ...
PMID:15315511 Ben-Menachem E; Epilepsia 45 Suppl 6: 13-8 (2004)
For more Mechanism of Action (Complete) data for PREGABALIN (6 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 165M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 165MG
USFDA APPLICATION NUMBER - 209501
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 330M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 330MG
USFDA APPLICATION NUMBER - 209501
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 82.5...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 82.5MG
USFDA APPLICATION NUMBER - 209501
DOSAGE - CAPSULE;ORAL - 100MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 150MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 200MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 225MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 25MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 300MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 50MG
USFDA APPLICATION NUMBER - 21446
DOSAGE - CAPSULE;ORAL - 75MG
USFDA APPLICATION NUMBER - 21446
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Granulation
Coating Systems & Additives
Taste Masking
Empty Capsules
Thickeners and Stabilizers
Lubricants & Glidants
Co-Processed Excipients
Film Formers & Plasticizers
Topical
Coloring Agents
Chewable & Orodispersible Aids
Emulsifying Agents
Disintegrants & Superdisintegrants
Parenteral
Controlled & Modified Release
Solubilizers
API Stability Enhancers
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
10
PharmaCompass offers a list of Pregabalin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pregabalin manufacturer or Pregabalin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pregabalin manufacturer or Pregabalin supplier.
PharmaCompass also assists you with knowing the Pregabalin API Price utilized in the formulation of products. Pregabalin API Price is not always fixed or binding as the Pregabalin Price is obtained through a variety of data sources. The Pregabalin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LYRICA CR manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LYRICA CR, including repackagers and relabelers. The FDA regulates LYRICA CR manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LYRICA CR API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LYRICA CR manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LYRICA CR supplier is an individual or a company that provides LYRICA CR active pharmaceutical ingredient (API) or LYRICA CR finished formulations upon request. The LYRICA CR suppliers may include LYRICA CR API manufacturers, exporters, distributors and traders.
click here to find a list of LYRICA CR suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LYRICA CR DMF (Drug Master File) is a document detailing the whole manufacturing process of LYRICA CR active pharmaceutical ingredient (API) in detail. Different forms of LYRICA CR DMFs exist exist since differing nations have different regulations, such as LYRICA CR USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LYRICA CR DMF submitted to regulatory agencies in the US is known as a USDMF. LYRICA CR USDMF includes data on LYRICA CR's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LYRICA CR USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LYRICA CR suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The LYRICA CR Drug Master File in Japan (LYRICA CR JDMF) empowers LYRICA CR API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the LYRICA CR JDMF during the approval evaluation for pharmaceutical products. At the time of LYRICA CR JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of LYRICA CR suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LYRICA CR Drug Master File in Korea (LYRICA CR KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LYRICA CR. The MFDS reviews the LYRICA CR KDMF as part of the drug registration process and uses the information provided in the LYRICA CR KDMF to evaluate the safety and efficacy of the drug.
After submitting a LYRICA CR KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LYRICA CR API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LYRICA CR suppliers with KDMF on PharmaCompass.
A LYRICA CR CEP of the European Pharmacopoeia monograph is often referred to as a LYRICA CR Certificate of Suitability (COS). The purpose of a LYRICA CR CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of LYRICA CR EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of LYRICA CR to their clients by showing that a LYRICA CR CEP has been issued for it. The manufacturer submits a LYRICA CR CEP (COS) as part of the market authorization procedure, and it takes on the role of a LYRICA CR CEP holder for the record. Additionally, the data presented in the LYRICA CR CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the LYRICA CR DMF.
A LYRICA CR CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. LYRICA CR CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of LYRICA CR suppliers with CEP (COS) on PharmaCompass.
A LYRICA CR written confirmation (LYRICA CR WC) is an official document issued by a regulatory agency to a LYRICA CR manufacturer, verifying that the manufacturing facility of a LYRICA CR active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LYRICA CR APIs or LYRICA CR finished pharmaceutical products to another nation, regulatory agencies frequently require a LYRICA CR WC (written confirmation) as part of the regulatory process.
click here to find a list of LYRICA CR suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LYRICA CR as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LYRICA CR API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LYRICA CR as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LYRICA CR and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LYRICA CR NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LYRICA CR suppliers with NDC on PharmaCompass.
LYRICA CR Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LYRICA CR GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LYRICA CR GMP manufacturer or LYRICA CR GMP API supplier for your needs.
A LYRICA CR CoA (Certificate of Analysis) is a formal document that attests to LYRICA CR's compliance with LYRICA CR specifications and serves as a tool for batch-level quality control.
LYRICA CR CoA mostly includes findings from lab analyses of a specific batch. For each LYRICA CR CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LYRICA CR may be tested according to a variety of international standards, such as European Pharmacopoeia (LYRICA CR EP), LYRICA CR JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LYRICA CR USP).
